In Vitro Assessment of Cardiac Risk in Drug Discovery

Dovital uw gezondheid- en vitaliteitbevorderende producten
7 Bekeken
Med4Pets
Published
Learn how an hiPSC-CM model can help provide clear decision-making data for your project team that can avoid costly issues related to QTc and QRS cardiac liabilities in the clinic.

Presentations:

Opportunities to Leverage Non-clinical Data in a Regulatory Integrated QTc Assessment (Derek Leishman, Vice President Translational and Quantitative Toxicology, Eli Lilly and Company).

A Clinically Translatable hIPSC Cardiomyocyte Model to Predict QTc and QRS Cardiac Risk (Steve Jenkinson, Vice President Drug Discovery and Safety, Metrion Biosciences).

Chaired by Eddy Stevens, CSO, Metrion Biosciences.
Log in of aanmelden om een reactie te plaatsen.
Wees de eerste die een reactie plaatst.